Biosimilars and Interchangeables: What They Are and Why They Matter

Ha Kung Wong practices general intellectual property law with an emphasis on complex patent and trade secret litigation in pharmaceuticals, biologics and chemistry. Cases Ha Kung has litigated include those related to proton pump inhibitors, anti-epileptic drugs, anti-tussives, psychotropic agents, siRNA and other pharmaceuticals. Mr. Wong also has extensive experience with inter partes review (IPR), post grant review (PGR), intellectual property counseling, pre-suit investigations, licensing and due diligence.

Mr. Wong is the recipient of the 2017 ILO Client Choice Individual Award for Intellectual Property in New York, was named to The National Law Journal’s 2017 inaugural list of Elite Boutique Trailblazers and was recognized as a 2018 LMG Life Sciences Star. He serves as faculty for NITA (the National Institute of Trial Advocacy) and Lawline, and has been named a Furthered 40 by Lawline for his contributions. He is also an Advisory Board Member for The Center for Biosimilars.

John Kirkland is Director of Intellectual Property at Alkermes, Inc. in Waltham, Massachusetts. At Alkermes, Mr. Kirkland has responsibility for all aspects of U.S. patent disputes, in both judicial and administrative tribunals. Prior to joining Alkermes, Mr. Kirkland was Counsel at Fitzpatrick, Cella, Harper & Scinto, where he advised clients in all aspects of intellectual property matters, including disputes arising under the Hatch Waxman Act.